NDA 220305 · Kura
Komzifti
Ziftomenib · Oral · Menin Inhibitor
NovelBreakthrough therapyPriority reviewOrphanCDER novel approval, Nov 13, 2025: To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options
Last checked: Nov 21, 2026Latest source record: Nov 13, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Nov 13, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
16
1 Phase 3, 12 recruiting
FAERS reports
74
41 serious, 19 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: DIFFERENTIATION SYNDROME Differentiation syndrome, which can be fatal, has occurred with KOMZIFTI. Signs and symptoms may include fever, joint pain, hypotension, hypoxia, dyspnea, rapid weight gain or peripheral edema, pleural or pericardial effusions, pulmonary infiltrates, acute kidney injury, and rashes. If differentiation syndrome is suspected, interrupt KOMZIFTI and initiate oral or intravenous corticosteroids with hemodynamic and laboratory monitoring until symptom resolution; resume KOMZIFTI upon symptom improvement [see Dosage and Administration ( 2.5 ), Warnings and Precautions ( 5.1 ), and Adverse Reactions ( 6.1 )] . WARNING: DIFFERENTIATION SYNDROME See full prescribing information for complete boxed warning. Differentiation syndrome, which can be fatal, has occurred with KOMZIFTI. If differentiation syndrome is suspected, interrupt KOMZIFTI and initiate oral or...
What it is approved for
From the label in effect Dec 9, 2025.
KOMZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14 )] . KOMZIFTI is a menin inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options. ( 1 )
Mechanism: Ziftomenib is a menin inhibitor that blocks the interaction of menin and lysine [K]-specific methyltransferase 2A (KMT2A). Acute leukemias can be driven by mutations in NPM1 that recruit the wild-type menin-KMT2A complex to promoters of leukemogenic genes. Susceptible NPM1 mutations are defined as those that result in loss of the nucleolar localization signal and the insertion of a new nuclear export signal leading to cytoplasmic accumulation of mutant NPM1 protein that disrupts normal cell function and drives leukemogenesis through altered gene expression. Pharmacologic disruption of the...
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 13, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterReviewLabel
1 products under this application
- KOMZIFTI · ZIFTOMENIB 200MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ziftomenib" as an intervention, any sponsor and status, largest first.
- Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLPivotal-lookingRecruiting
Kura Oncology, Inc.Industry
NCT07007312 · 1,300 participants (planned) · Start Sep 26, 2025 · Primary completion Nov 2031
Drug: Ziftomenib; Placebo and 4 more · For: Acute Myeloid Leukemia (AML)
Sites: Gilbert, Arizona; Clovis, California; La Jolla, California · 141 sites in all
Kura Oncology, Inc.Industry
NCT05735184 · 420 participants (planned) · Start Jul 18, 2023 · Primary completion Apr 2030
Drug: Ziftomenib; Venetoclax and 4 more · For: Acute Myeloid Leukemia; Mixed Lineage Leukemia Gene Mutation; Refractory AML and 7 more
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 44 sites in all
- First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid LeukemiaPivotal-lookingActive, not recruiting
Kura Oncology, Inc.Industry
NCT04067336 · 263 participants (planned) · Start Sep 12, 2019 · Primary completion Oct 16, 2028
Drug: Ziftomenib; Midazolam and 1 more · For: Advanced Malignant Neoplasm; Acute Myeloid Leukemia; Mixed Lineage Leukemia and 4 more
Sites: Gilbert, Arizona; Los Angeles, California; Jacksonville, Florida · 43 sites in all
Kura Oncology, Inc.Industry
NCT06001788 · 171 participants (planned) · Start Feb 22, 2024 · Primary completion Dec 2026
Drug: Ziftomenib; Fludarabine and 4 more · For: AML; AML With Mutated NPM1; Hematologic Malignancy and 9 more
Sites: Gilbert, Arizona; Los Angeles, California; Orange, California · 45 sites in all
Kura Oncology, Inc.Industry
NCT06655246 · 135 participants (planned) · Start Mar 27, 2025 · Primary completion Jun 2029
Drug: ziftomenib; imatinib mesylate · For: Gastrointestinal Stromal Tumor (GIST); Gastrointestinal Stromal Cancer; Gastrointestinal Stromal Neoplasm and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; La Jolla, California · 32 sites in all
- Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDSPivotal-lookingNot yet recruiting
Kura Oncology, Inc.Industry
NCT07929740 · 126 participants (planned) · Start Oct 30, 2026 · Primary completion Feb 28, 2029
Drug: Ziftomenib; Ziftomenib and 2 more · For: Myelodysplastic Syndrome (MDS)/AML; Myeloid Leukemia, Acute
Tanja Andrea GruberAcademic, hospital or other
NCT05848687 · 90 participants (planned) · Start Nov 3, 2023 · Primary completion Dec 2028
Drug: Dexamethasone; Mitoxantrone and 7 more · For: Lymphoblastic Leukemia
Sites: Phoenix, Arizona; Little Rock, Arkansas; Los Angeles, California · 24 sites in all
Uma BorateAcademic, hospital or other
NCT06930352 · 70 participants (planned) · Start Jan 15, 2027 · Primary completion Jan 31, 2028
Drug: Cytarabine; Hydroxyurea and 1 more · For: Acute Myeloid Leukemia
Sites: Columbus, Ohio
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death18
- pruritus9
- off label use8
- asthenia6
- platelet count decreased5
- product use in unapproved indication5
- differentiation syndrome4
- infection4
- nausea4
- drug ineffective3
- fatigue3
- pericarditis3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 5 |
| 2026 | 69 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.
Wang ES, Montesinos P, Foran J, et al. · J Clin Oncol 2025 · Clinical Trial, Phase II, Clinical Trial, Phase I
- Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.
Wang ES, Issa GC, Erba HP, et al. · Lancet Oncol 2024 · Clinical Trial, Phase I, Multicenter Study
- Ziftomenib with venetoclax and azacitidine for relapsed/refractory NPM1-mutated acute myeloid leukemia.
Wang ES, Erba H, Zeidan AM, et al. · Blood 2026 · Clinical Trial, Phase I
- Pharmacokinetics and ADME Characterization After Oral and Intravenous Administration of [14C]-Ziftomenib in Healthy Male Participants.
Mitra A, Ahsan JM, Tabachri M, et al. · Clin Transl Sci 2025 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
Sponsor: Kura
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.